A systematic review of randomized controlled trials of bupropion versus methylphenidate in the treatment of attention-deficit/ hyperactivity disorder

Neuropsychiatric Disease and Treatment

Volumn 10, Issue , 2014, Pages 1439-1449

  Maneeton, Narong ^a   Maneeton, Benchalak ^a   Intaprasert, Suthi ^a   Woottiluk, Pakapan ^b  

^a Department of Psychiatry ^*  (Thailand)

^b CHIANG MAI UNIVERSITY   (Thailand)

Author keywords

Acceptability; ADHD; Bupropion; Methylphenidate; Systematic review; Tolerability

Indexed keywords

AMFEBUTAMONE; METHYLPHENIDATE;

ADOLESCENT; ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; REMISSION; RISK FACTOR; SCORING SYSTEM; SYSTEMATIC REVIEW; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 84905451170     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S62714     Document Type: Article

References (49)

1. Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007;164(6):942-948.
2. Montiel C, Pena JA, Montiel-Barbero I, Polanczyk G. Prevalence rates of attention deficit/hyperactivity disorder in a school sample of Venezuelan children. Child Psychiatry Hum Dev. 2008;39(3):311-322.
3. Polanczyk G, Rohde LA. Epidemiology of attention-deficit/hyperactivity disorder across the lifespan. Curr Opin Psychiatry. 2007;20(4): 386-392.
4. Simon V, Czobor P, Balint S, Meszaros A, Bitter I. Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis. Br J Psychiatry. 2009;194(3):204-211.
5. Barkley RA, Grodzinsky G, DuPaul GJ. Frontal lobe functions in attention deficit disorder with and without hyperactivity: a review and research report. J Abnorm Child Psychol. 1992;20(2):163-188.
6. Clark C, Prior M, Kinsella GJ. Do executive function deficits differentiate between adolescents with ADHD and oppositional defiant/conduct disorder? A neuropsychological study using the Six Elements Test and Hayling Sentence Completion Test. J Abnorm Child Psychol. 2000; 28(5):403-414.
7. Weiss G, Hechtman L, Milroy T, Perlman T. Psychiatric status of hyperactives as adults: a controlled prospective 15-year follow-up of 63 hyperactive children. J Am Acad Child Psychiatry. 1985;24(2): 211-220.
8. Davidson MA. ADHD in adults: a review of the literature. J Atten Disord. 2008;11(6):628-641.
9. Mordre M, Groholt B, Sandstad B, Myhre AM. The impact of ADHD symptoms and global impairment in childhood on working disability in mid-adulthood: a 28-year follow-up study using official disability pension records in a high-risk in-patient population. BMC Psychiatry. 2012;12:174.
10. Dulcan MK, Benson RS. AACAP Official Action. Summary of the practice parameters for the assessment and treatment of children, adolescents, and adults with ADHD. J Am Acad Child Adolesc Psychiatry. 1997;36(9):1311-1317.
11. Arnsten AF. Stimulants: therapeutic actions in ADHD. Neuropsychopharmacology. 2006;31(11):2376-2383.
12. Mohammadi M, Akhondzadeh S. Advances and considerations in attention-deficit/hyperactivity disorder pharmacotherapy. Acta Medica Iranica. 2011;49(8):487-498.
13. Rosler M, Fischer R, Ammer R, Ose C, Retz W. A randomised, placebocontrolled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder. Eur Arch Psychiatry Clin Neurosci. 2009;259(2):120-129.
14. Biederman J, Mick E, Surman C, et al. A randomized, 3-phase, 34-week, double-blind, long-term efficacy study of osmotic-release oral systemmethylphenidate in adults with attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2010;30(5):549-553.
15. Sonuga-Barke EJ, Coghill D, Wigal T, DeBacker M, Swanson J. Adverse reactions to methylphenidate treatment for attention-deficit/hyperactivity disorder: structure and associations with clinical characteristics and symptom control. J Child Adolesc Psychopharmacol. 2009;19(6):683-690.
16. Zhang H, Du M, Zhuang S. Impact of long-term treatment of methylphenidate on height and weight of school age children with ADHD. Neuropediatrics. 2010;41(2):55-59.
17. Conners CK, Casat CD, Gualtieri CT, et al. Bupropion hydrochloride in attention deficit disorder with hyperactivity. J Am Acad Child Adolesc Psychiatry. 1996;35(10):1314-1321.
18. Maneeton N, Maneeton B, Srisurapanont M, Martin SD. Bupropion for adults with attention-deficit hyperactivity disorder: meta-analysis of randomized, placebo-controlled trials. Psychiatry Clin Neurosci. 2011;65(7):611-617.
19. Barrickman LL, Perry PJ, Allen AJ, et al. Bupropion versus methylphenidate in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1995;34(5):649-657.
20. Kuperman S, Perry PJ, Gaffney GR, et al. Bupropion SR vs methylphenidate vs placebo for attention deficit hyperactivity disorder in adults. Ann Clin Psychiatry. 2001;13(3):129-134.
21. Levin FR, Evans SM, Brooks DJ, Kalbag AS, Garawi F, Nunes EV. Treatment of methadone-maintained patients with adult ADHD: doubleblind comparison of methylphenidate, bupropion and placebo. Drug Alcohol Depend. 2006;81(2):137-148.
22. Jafarinia M, Mohammadi MR, Modabbernia A, et al. Bupropion versus methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder: randomized double-blind study. Hum Psychopharmacol. 2012;27(4):411-418.
23. Soroko FE, Mehta NB, Maxwell RA, Ferris RM, Schroeder DH. Bupropion hydrochloride ((+/-) alpha-t-butylamino-3-chloropropiophenone HCl): a novel antidepressant agent. J Pharm Pharmacol. 1977;29(12):767-770.
24. Barison F, Massignan L. Rassegna di neuropsichiatria e scienze affini [Observations on neurotic depressions with reference to a combined serpasil-ritalin treatment]. Rass Neuropsichiatr 1956;10(5-6):198-209. Italian.
25. Higgins JPT, Altman DG. Assessing risk of bias in included studies. In: Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (Updated March 2011). The Cochrane Collaboration; 2009. Available from: http://www.cochranehandbook.org. Accessed June 6, 2014.
26. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multipletreatments meta-analysis. Lancet. 2009;373(9665):746-758.
27. Papakostas GI. Tolerability of modern antidepressants. J Clin Psychiatry. 2008;69 Suppl E1:8-13.
28. Wiebe N, Vandermeer B, Platt RW, Klassen TP, Moher D, Barrowman NJ. A systematic review identifies a lack of standardization in methods for handling missing variance data. J Clin Epidemiol. 2006;59(4): 342-353.
29. Sterne JAC, Egger M, Moher D. Addressing reporting biases. In: Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (Updated March 2011). The Cochrane Collaboration; 2009. Available from: http://www.cochranehandbook.org. Accessed June 6, 2014.
30. Loney J, Milich R. Hyperactivity, inattention, and aggression in clinical practice. In: Wolraich M, Routh DK, editors. Advances in developmental and behavioral pediatrics. Greenwich, CT: JAI; 1982:113-147.
31. Dupaul GJ, Power TJ, Anastopoulos AD, Reid R. ADHD Rating Scale-IV: Checklists, norms, and clinical interpretation. New York: Guilford Press; 1998.
32. Lee J, Grizenko N, Bhat V, Sengupta S, Polotskaia A, Joober R. Relation between therapeutic response and side effects induced by methylphenidate as observed by parents and teachers of children with ADHD. BMC Psychiatry. 2011;11:70.
33. Wilens TE, Adler LA, Adams J, et al. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J Am Acad Child Adolesc Psychiatry. 2008;47(1):21-31.
34. Sembower MA, Ertischek MD, Buchholtz C, Dasgupta N, Schnoll SH. Surveillance of diversion and nonmedical use of extended-release prescription amphetamine and oral methylphenidate in the United States. J Addict Dis. 2013;32(1):26-38.
35. Biederman J, Baldessarini RJ, Wright V, Knee D, Harmatz JS. A double-blind placebo controlled study of desipramine in the treatment of ADD: I. Efficacy. J Am Acad Child Adolesc Psychiatry. 1989;28(5): 777-784.
36. Singer HS, Brown J, Quaskey S, Rosenberg LA, Mellits ED, Denckla MB. The treatment of attention-deficit hyperactivity disorder in Tourette's syndrome: a double-blind placebo-controlled study with clonidine and desipramine. Pediatrics. 1995;95(1):74-81.
37. Wilens TE, Biederman J, Prince J, et al. Six-week, double-blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder. Am J Psychiatry. 1996;153(9):1147-1153.
38. Spencer T, Biederman J, Coffey B, et al. A double-blind comparison of desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 2002;59(7):649-656.
39. Riddle MA, Geller B, Ryan N. Another sudden death in a child treated with desipramine. J Am Acad Child Adolesc Psychiatry. 1993;32(4): 792-797.
40. Pataki CS, Carlson GA, Kelly KL, Rapport MD, Biancaniello TM. Side effects of methylphenidate and desipramine alone and in combination in children. J Am Acad Child Adolesc Psychiatry. 1993;32(5): 1065-1072.
41. Ratner S, Laor N, Bronstein Y, Weizman A, Toren P. Six-week openlabel reboxetine treatment in children and adolescents with attentiondeficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2005;44(5):428-433.
42. Arabgol F, Panaghi L, Hebrani P. Reboxetine versus methylphenidate in treatment of children and adolescents with attention deficithyperactivity disorder. Eur Child Adolesc Psychiatry. 2009;18(1): 53-59.
43. Riahi F, Tehrani-Doost M, Shahrivar Z, Alaghband-Rad J. Efficacy of reboxetine in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled clinical trial. Hum Psychopharmacol. 2010;25(7-8):570-576.
44. Zarinara AR, Mohammadi MR, Hazrati N, et al. Venlafaxine versus methylphenidate in pediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial. Hum Psychopharmacol. 2010;25(7-8):530-535.
45. Amiri S, Farhang S, Ghoreishizadeh MA, Malek A, Mohammadzadeh S. Double-blind controlled trial of venlafaxine for treatment of adults with attention deficit/hyperactivity disorder. Hum Psychopharmacol. 2012;27(1):76-81.
46. Kratochvil CJ, Heiligenstein JH, Dittmann R, et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry. 2002;41(7):776-784.
47. Overtoom CC, Verbaten MN, Kemner C, et al. Effects of methylphenidate, desipramine, and L-dopa on attention and inhibition in children with attention deficit hyperactivity disorder. Behav Brain Res. 17, 2003; 145(1/2):7-15.
48. Simmler LD, Wandeler R, Liechti ME. Bupropion, methylphenidate, and 3,4-methylenedioxypyrovalerone antagonize methamphetamineinduced efflux of dopamine according to their potencies as dopamine uptake inhibitors: implications for the treatment of methamphetamine dependence. BMC Res Notes. 2013;6:220.
49. Nieuwstraten CE, Dolovich LR. Bupropion versus selective serotoninreuptake inhibitors for treatment of depression. Ann Pharmacother. 2001;35(12):1608-1613.